AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34964489 — intervention group
Group type: EXPERIMENTAL
Intervention: Reviewer-adjusted count
Number of subjects: 80
Study 34964489 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual count
Number of subjects: 80
Study 34964489 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated algorithm
Number of subjects: 80
Study 33899783 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple-based intervention consisting of 3 advanced nurse-led, face-to-face sessions supported by web-based information
Number of subjects: 60
Study 33899783 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple-based intervention
Number of subjects: 60
Study 32986531 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiotaping (KT)
Number of subjects: 52
Study 32986531 — intervention group
Group type: COMPARATOR
Intervention: No Kinesiotaping (no-KT)
Number of subjects: 52
Study 33318452 — intervention group
Group type: EXPERIMENTAL
Intervention: Training by novice trainers
Number of subjects: 24
Study 33318452 — intervention group
Group type: COMPARATOR
Intervention: Training by experienced trainers
Number of subjects: 24
Study 34436714 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management intervention with cash incentives (up to $3650 per year)
Number of subjects: 0
Study 34436714 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 33385757 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Treatment (IT)
Number of subjects: 303
Study 33385757 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Treatment (ST)
Number of subjects: 303
Study 33385757 — intervention group
Group type: EXPERIMENTAL
Intervention: No current alcohol use
Number of subjects: 303
Study 33385757 — intervention group
Group type: COMPARATOR
Intervention: Problematic alcohol use
Number of subjects: 303
Study 33385757 — intervention group
Group type: COMPARATOR
Intervention: Problematic use by study arm interaction
Number of subjects: 303
Study 35348459 — intervention group
Group type: EXPERIMENTAL
Intervention: Fex-Can intervention (web-based, 12-week duration)
Number of subjects: 124
Study 35348459 — intervention group
Group type: EXPERIMENTAL
Intervention: Fex-Can intervention
Number of subjects: 124
Study 35348459 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 124
Study 34836821 — intervention group
Group type: EXPERIMENTAL
Intervention: Transparent face mask worn by health care professionals (n = 83)
Number of subjects: 176
Study 34836821 — intervention group
Group type: COMPARATOR
Intervention: Standard non-transparent face mask worn by health care professionals (n = 93)
Number of subjects: 176
Study 34836821 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses (initial assessment)
Number of subjects: 176
Study 34836821 — intervention group
Group type: EXPERIMENTAL
Intervention: Physicians (15 minutes later assessment)
Number of subjects: 176
Study 34836821 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrepancy in VAS scores between nurses and physicians
Number of subjects: 176
Study 33501599 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D whole heart volume (WHV) derived from non‐contrast cardiac computed tomography (CT)
Number of subjects: 3798
Study 33501599 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D whole heart volume (WHV)
Number of subjects: 3798
Study 36216413 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented Reality Rehabilitation of Walking-Cerebral Palsy AVG
Number of subjects: 14
Study 36216413 — intervention group
Group type: COMPARATOR
Intervention: Treadmill gait training (control)
Number of subjects: 14
Study 33836723 — intervention group
Group type: EXPERIMENTAL
Intervention: Volunteer based information on waste segregation (I-MISS)
Number of subjects: 425
Study 33836723 — intervention group
Group type: COMPARATOR
Intervention: Existing routine waste segregation information (Control)
Number of subjects: 425
Study 32515006 — intervention group
Group type: EXPERIMENTAL
Intervention: Volumetric laser endomicroscopy (VLE) full scans
Number of subjects: 29
Study 33213527 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamlodipine 5 mg (fasted)
Number of subjects: 48
Study 33213527 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 10 mg (fasted)
Number of subjects: 48
Study 33213527 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamlodipine 5 mg (fed)
Number of subjects: 48
Study 33213527 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 10 mg (fed)
Number of subjects: 48
Study 36429677 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity plyometric exercise (MIPE)
Number of subjects: 37
Study 36429677 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity plyometric exercise (HIPE)
Number of subjects: 37
Study 36429677 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity plyometric exercise (LIPE)
Number of subjects: 37
Study 34706311 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab (60 mg subcutaneous every 6 months) added to intensive urate-lowering therapy (ULT)
Number of subjects: 20
Study 34706311 — intervention group
Group type: COMPARATOR
Intervention: Intensive urate-lowering therapy (ULT) alone
Number of subjects: 20
Study 34706311 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab/ULT
Number of subjects: 20
Study 34706311 — intervention group
Group type: COMPARATOR
Intervention: ULT alone
Number of subjects: 20
Study 32011496 — intervention group
Group type: EXPERIMENTAL
Intervention: Phellinus linteus (PL) 1000 mg
Number of subjects: 3
Study 32011496 — intervention group
Group type: EXPERIMENTAL
Intervention: Phellinus linteus (PL) 2000 mg
Number of subjects: 3
Study 32011496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 35512507 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week emotional support programme
Number of subjects: 0
Study 35512507 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study 32012346 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: prefabricated zirconia abutment with pressed ceramic
Number of subjects: 20
Study 32012346 — intervention group
Group type: COMPARATOR
Intervention: Group B: individualized CAD/CAM zirconia abutment with hand-layered technique
Number of subjects: 20
Study 32012346 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 36501004 — intervention group
Group type: EXPERIMENTAL
Intervention: 392 mg/day of blackcurrant powder (low blackcurrant, BC, group, n = 16)
Number of subjects: 40
Study 36501004 — intervention group
Group type: EXPERIMENTAL
Intervention: 784 mg/day of blackcurrant powder (high BC group, n = 11)
Number of subjects: 40
Study 36501004 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group, n = 13)
Number of subjects: 40
Study 34185664 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucoadhesive tablet containing pilocarpine, 5 mg
Number of subjects: 25
Study 34185664 — intervention group
Group type: COMPARATOR
Intervention: Mucoadhesive tablet without the active ingredient
Number of subjects: 25
Study 35839010 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal femoral nail antirotation (PFNA)
Number of subjects: 87
Study 35839010 — intervention group
Group type: COMPARATOR
Intervention: External fixation
Number of subjects: 87
Study 32462276 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine sound dentin
Number of subjects: 120
Study 32462276 — intervention group
Group type: EXPERIMENTAL
Intervention: Human dentin
Number of subjects: 120
Study 32462276 — intervention group
Group type: EXPERIMENTAL
Intervention: pH-cycling
Number of subjects: 120
Study 32462276 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine dentin
Number of subjects: 120
Study 32462276 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexural strength (MPa)
Number of subjects: 120
Study 32462276 — intervention group
Group type: EXPERIMENTAL
Intervention: Compositional variables (i.e., PO4/amide I, CI, and %mineral)
Number of subjects: 120
Study 36265171 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical dilators used concurrently with misoprostol
Number of subjects: 0
Study 36265171 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 32597686 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-pressure vacuum drain (n = 15)
Number of subjects: 35
Study 32597686 — intervention group
Group type: COMPARATOR
Intervention: Control group (without vacuum drain) (n = 20)
Number of subjects: 35
Study 32977777 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical conditions (treatment)
Number of subjects: 2909
Study 32977777 — intervention group
Group type: EXPERIMENTAL
Intervention: Deaths outside health facility (surgical conditions)
Number of subjects: 2909
Study 32977777 — intervention group
Group type: COMPARATOR
Intervention: Deaths from other medical conditions
Number of subjects: 2909
Study 32977777 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical care received
Number of subjects: 2909
Study 32977777 — intervention group
Group type: EXPERIMENTAL
Intervention: Health care sought
Number of subjects: 2909
Study 34373362 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium alginate (orally administered for 3 days after EGD)
Number of subjects: 210
Study 34373362 — intervention group
Group type: COMPARATOR
Intervention: Control group (no sodium alginate)
Number of subjects: 210
Study 34373362 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group (sodium alginate)
Number of subjects: 210
Study 33050934 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezepelumab
Number of subjects: 1061
Study 33050934 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1061
Study 35108114 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus peer-befriending (six visits between randomisation and four months)
Number of subjects: 56
Study 35108114 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 56
Study 33953741 — intervention group
Group type: COMPARATOR
Intervention: Bifrontal tDCS with anode over the left dorsolateral prefrontal cortex
Number of subjects: 25
Study 33953741 — intervention group
Group type: COMPARATOR
Intervention: Frontoparietal tDCS
Number of subjects: 25
Study 32406989 — intervention group
Group type: EXPERIMENTAL
Intervention: Health facility delivery of CHoBI7 plus mHealth (weekly voice and text messages) (no home visits)
Number of subjects: 1468
Study 32406989 — intervention group
Group type: EXPERIMENTAL
Intervention: Health facility delivery of CHoBI7 plus two home visits and mHealth
Number of subjects: 1468
Study 32406989 — intervention group
Group type: COMPARATOR
Intervention: Standard recommendation on oral rehydration solution use
Number of subjects: 1468
Study 34488548 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention (20 to 30 minutes)
Number of subjects: 44
Study 34488548 — intervention group
Group type: COMPARATOR
Intervention: Control group (5 minutes of brief advice)
Number of subjects: 44
Study 34915725 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Interpersonal Psychotherapy (IPT-G)
Number of subjects: 24
Study 34915725 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control
Number of subjects: 24
Study 34915725 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy adherence
Number of subjects: 24
Study 34472894 — intervention group
Group type: EXPERIMENTAL
Intervention: Good Behavior Game (GBG) intervention
Number of subjects: 3084
Study 34472894 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (control group)
Number of subjects: 3084
Study 32912218 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week complex interventions including structured assessment, health education, goal empowerment, and care coordination supported by a health-social team
Number of subjects: 75
Study 32912218 — intervention group
Group type: COMPARATOR
Intervention: Usual discharge care and monthly social call
Number of subjects: 75
Study 35831850 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B6 (80 mg daily)
Number of subjects: 90
Study 35831850 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 33152774 — intervention group
Group type: EXPERIMENTAL
Intervention: M-ESD
Number of subjects: 60
Study 33152774 — intervention group
Group type: COMPARATOR
Intervention: C-ESD
Number of subjects: 60
Study 35997099 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced counseling (whistling Flo-tone + smartphone application combined with traditional verbal counseling)
Number of subjects: 100
Study 35997099 — intervention group
Group type: COMPARATOR
Intervention: Traditional verbal counseling
Number of subjects: 100
Study 33463912 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval exercise (57.6 kJ/exercise session)
Number of subjects: 11
Study 33463912 — intervention group
Group type: COMPARATOR
Intervention: Continuous exercise (12 min)
Number of subjects: 11
Study 32159820 — intervention group
Group type: EXPERIMENTAL
Intervention: Wavefront-Guided PRK (WFG)
Number of subjects: 20
Study 32159820 — intervention group
Group type: COMPARATOR
Intervention: Wavefront-Optimized PRK (WFO)
Number of subjects: 20
Study 32159820 — intervention group
Group type: EXPERIMENTAL
Intervention: Both WFG and WFO PRK
Number of subjects: 20
Study 34473302 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher urine interleukin‐18
Number of subjects: 2377
Study 34473302 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher kidney injury molecule‐1 (KIM-1)
Number of subjects: 2377
Study 34473302 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher neutrophil gelatinase‐associated lipocalin (NGAL)
Number of subjects: 2377
Study 34473302 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher monocyte chemoattractant protein‐1 (MCP‐1)
Number of subjects: 2377
Study 34473302 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower urine uromodulin (UMOD)
Number of subjects: 2377
Study 34473302 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher serum fibroblast growth factor‐23
Number of subjects: 2377
Study 33826436 — intervention group
Group type: EXPERIMENTAL
Intervention: IOPTx™ system (wearable electroceutical treatment)
Number of subjects: 0
Study 32572040 — intervention group
Group type: EXPERIMENTAL
Intervention: Genes controlling ginsenoside biosynthesis in ginseng
Number of subjects: 3
Study 32572040 — intervention group
Group type: EXPERIMENTAL
Intervention: Genes controlling fiber length in cotton
Number of subjects: 3
Study 32572040 — intervention group
Group type: EXPERIMENTAL
Intervention: Genes controlling grain yield in maize
Number of subjects: 3
Study 35633978 — intervention group
Group type: EXPERIMENTAL
Intervention: Dance and yoga intervention (twice a week for 8 months)
Number of subjects: 121
Study 35633978 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 121
Study 33077708 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple myeloma patients
Number of subjects: 167
Study 33077708 — intervention group
Group type: COMPARATOR
Intervention: Noncancer patients
Number of subjects: 167
Study 34966032 — intervention group
Group type: EXPERIMENTAL
Intervention: LEADS curriculum
Number of subjects: 110
Study 34966032 — intervention group
Group type: EXPERIMENTAL
Intervention: TeamSTEPPS curriculum
Number of subjects: 110
Study 34966032 — intervention group
Group type: COMPARATOR
Intervention: Active controls (no leadership curriculum)
Number of subjects: 110
Study 33966242 — intervention group
Group type: EXPERIMENTAL
Intervention: INVOS neonatal sensor with cover
Number of subjects: 0
Study 33966242 — intervention group
Group type: EXPERIMENTAL
Intervention: INVOS neonatal sensor without cover
Number of subjects: 0
Study 33966242 — intervention group
Group type: COMPARATOR
Intervention: OxiplexTS reference oximeter
Number of subjects: 0
Study 36429876 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based interactive weight loss coaching
Number of subjects: 1499
Study 36429876 — intervention group
Group type: COMPARATOR
Intervention: Non-interactive web-based health program
Number of subjects: 1499
Study 34739635 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular-based recommended therapy (MBRT) proposed after molecular profiling
Number of subjects: 141
Study 34739635 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 141
Study 34739635 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 141
Study 34739635 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 141
Study 34739635 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 141
Study 34739635 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of MBRT
Number of subjects: 141
Study 34739635 — intervention group
Group type: EXPERIMENTAL
Intervention: Actionable molecular alterations identified
Number of subjects: 141
Study 34739635 — intervention group
Group type: EXPERIMENTAL
Intervention: High-throughput sequencing
Number of subjects: 141
Study 34739635 — intervention group
Group type: EXPERIMENTAL
Intervention: Criteria for clinical trial enrollment
Number of subjects: 141
Study 32559515 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged-release fampridine (PR-fampridine)
Number of subjects: 61
Study 32559515 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 32559515 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged-release fampridine (PR-fampridine) in a sub-group (n = 8)
Number of subjects: 61
Study 33673567 — intervention group
Group type: EXPERIMENTAL
Intervention: Received caffeine (3 mg/kg)
Number of subjects: 12
Study 33673567 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed caffeine (placebo but participants were told it was caffeine)
Number of subjects: 12
Study 33673567 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cellulose, 3 mg/kg)
Number of subjects: 12
Study 33673567 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed caffeine (placebo)
Number of subjects: 12
Study 33673567 — intervention group
Group type: COMPARATOR
Intervention: Placebo, Received caffeine, Informed caffeine
Number of subjects: 12
Study 34313619 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous supplementation
Number of subjects: 52
Study 34313619 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 34313619 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (short-acting, twice daily)
Number of subjects: 52
Study 33896630 — intervention group
Group type: EXPERIMENTAL
Intervention: B. coagulans-70
Number of subjects: 30
Study 33896630 — intervention group
Group type: COMPARATOR
Intervention: Control group (other tested strains)
Number of subjects: 30
Study 32900564 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg 2 hours after TKA, followed by 200 mg 6 hours later
Number of subjects: 0
Study 32900564 — intervention group
Group type: COMPARATOR
Intervention: Control group received 400 mg of celecoxib the second day after surgery
Number of subjects: 0
Study 32171411 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Number of subjects: 0
Study 32171411 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting
Number of subjects: 0
Study 34286867 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-assisted scaling and root planing (L-SRP)
Number of subjects: 26
Study 34286867 — intervention group
Group type: COMPARATOR
Intervention: Conventional scaling and root planing (C-SRP)
Number of subjects: 26
Study 33705465 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated collaborative care intervention
Number of subjects: 409
Study 34992671 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine combined with propofol, remifentanil, and atracurium (Experimental Group)
Number of subjects: 80
Study 34992671 — intervention group
Group type: COMPARATOR
Intervention: Propofol, remifentanil, and atracurium only (Control Group)
Number of subjects: 80
Study 34992671 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound and spiral CT images before reconstruction
Number of subjects: 80
Study 34992671 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound and spiral CT images after reconstruction
Number of subjects: 80
Study 34895998 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet patterned after the 2010 Dietary Guidelines for Americans (DGA)
Number of subjects: 44
Study 34895998 — intervention group
Group type: COMPARATOR
Intervention: Typical American Diet (TAD)
Number of subjects: 44
Study 34161737 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (40 minutes, 50-70% heart rate reserve, 3-4 times per week)
Number of subjects: 27
Study 34161737 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 27
Study 34161737 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study 35649615 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal health coaching by telephone and access to a smartphone and web application for 1 year
Number of subjects: 90
Study 35649615 — intervention group
Group type: COMPARATOR
Intervention: Access to the application for 1 year and a one-time written diet and exercise recommendation
Number of subjects: 90
Study 33297757 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnofertility-based nursing care
Number of subjects: 61
Study 32386082 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative intermediate care
Number of subjects: 286
Study 32386082 — intervention group
Group type: COMPARATOR
Intervention: Standard surgical ward care
Number of subjects: 286
Study 36478180 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide (once-weekly subcutaneous)
Number of subjects: 0
Study 36478180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33949065 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based multi-component psycho-educational intervention (GMC-PEI)
Number of subjects: 54
Study 33949065 — intervention group
Group type: COMPARATOR
Intervention: Control group (leaflets containing information about dementia)
Number of subjects: 54
Study 32539096 — intervention group
Group type: EXPERIMENTAL
Intervention: Viltolarsen
Number of subjects: 0
Study 32539096 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 34801917 — intervention group
Group type: EXPERIMENTAL
Intervention: Midodrine (10 mg every 8 hours)
Number of subjects: 62
Study 34801917 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 62
Study 34170908 — intervention group
Group type: EXPERIMENTAL
Intervention: IV furosemide infusion
Number of subjects: 94